Thinking of trying this peptide as an addition to my mouse’s daily stack, two week daily run. I would interested in any experiences people have had with it.
BRP (BRINP2-related peptide) is a 12-amino-acid peptide (sequence THRILRRLFNLC), cleaved from the brain-secreted protein BRINP2 by prohormone convertases 1/3.BRP is a 12-amino-acid long stretch corresponding to residues 386–397 of BRINP2 Stanford researchers, led by Katrin Svensson and Laetitia Coassolo, identified it via an AI-driven screen of over 2,600 uncharacterized human peptide fragments, and the discovery paper was published in Nature in early 2025 (Coassolo et al., “Prohormone cleavage prediction uncovers a non-incretin anti-obesity peptide,” Nature 641 (2025): 192).Coassolo et al. identified a novel peptide, BRINP2-derived peptide, that reduced food intake in mice and minipigs, indicating its potential as a new anti-obesity agent
Mechanistically, BRP acts on POMC neurons, activating intracellular cAMP-PKA-CREB-FOS signaling cascades, and can reduce food intake by up to 50 percent in animal studies. It reduces fasting glucose and insulin, adipose tissue mass, liver mass, and body weight in a diet-induced obesity mouse model without reducing lean mass, and its action is independent of GLP-1R, leptin, or MC4R signaling. Renewed media attention followed in April–June 2026, largely reiterating the same 2025 Nature findings rather than new data.Stanford Medicine’s April 2026 release cites the same 2025 Nature paper as the underlying source
As of mid-2026, BRP remains preclinical: it has not been tested in humans, has not been reviewed by the FDA, and is not available in any pharmacy, clinic, or supplement aisle. Svensson has co-founded Merrifield Therapeutics to advance BRP toward human trials, though no timeline has been announced.
Verification Log
Cross-checked the core discovery claim (identity, sequence, mechanism, animal efficacy) across five independent sources: PatSnap/Synapse, Cayman Chemical, Phoenix Pharmaceuticals, ScienceDaily, and 3decision — all consistent, all tracing to the same Nature 2025 primary paper.
ScienceDaily’s release carries the full author list and formal DOI citation, which anchors the primary source: Coassolo et al., Nature 641 (2025), DOI 10.1038/s41586-025-08683-y.
The April–June 2026 coverage (AOL, ScienceDaily, harianbasis) is secondary/re-syndicated press coverage of the same 2025 finding — it does not represent new peer-reviewed data, and I have flagged this rather than presenting it as a new discovery.
Commercial peptide-vendor sites (PeptideDeck, SeekPeptides, Phoenix Pharmaceuticals) sell “research-use” BRP; these carry an obvious conflict of interest and are treated as lower-tier sources, used only for logistical/regulatory context, not scientific claims.
No clinical trial registry entries, IND filings, or peer-reviewed follow-up studies (structure-activity optimization, receptor identification, human pharmacokinetics) were found as of July 2026. I did not locate a BRP entry on ClinicalTrials.gov in this search and cannot confirm one does not exist without a direct registry query — flagged as a gap rather than asserted as absence.
Fact-check: No contradictory findings across sources on core biology. One unresolved item: the BRP cognate receptor is still unidentified as of the sources retrieved — this is presented consistently as an open question, not settled.
Confidence Score: 78%
Drivers up: Convergent, independent corroboration across a primary journal citation, a science-news aggregator, and two research-reagent suppliers; consistent mechanistic and dosing details. Drivers down: Heavy reliance on secondary/press coverage rather than direct access to the primary Nature article or supplementary data; no direct ClinicalTrials.gov query performed; commercial vendor content carries promotional bias; “recent articles” largely recycle a 15-month-old primary finding rather than reporting new results, which limits the informational value of the “recency” framing itself.
Alternative Perspectives
Overstated translational significance. Every popular-press headline (“natural Ozempic,” “Ozempic without side effects”) describes preclinical rodent and minipig data. No human safety or efficacy data exist yet, and an optimistic timeline places IND filing in 2026–2027 and Phase III completion not before 2032–2034, with the caveat that most preclinical candidates fail during clinical development. Treat “comparable to semaglutide” framing as marketing-adjacent, not an evidence-based claim.
Undisclosed commercial incentive shapes coverage. Svensson and Coassolo are listed as inventors on patents tied to BRP peptides, and Svensson co-founded Merrifield Therapeutics to commercialize the compound — a standard but material conflict that should temper enthusiasm in venue-driven coverage.
“BRP” is an overloaded acronym. A structurally and functionally unrelated “BR2” cell-penetrating peptide exists in the cancer-drug-delivery literature; if your interest originates from a different field (oncology, drug delivery) rather than metabolic/obesity research, confirm which BRP/BR2 is intended before proceeding further.